Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon shares jumped nearly 10 per cent on Monday morning after the biopharma major received approval from the Drugs Controller General of India (DCGI) to market its novel biologic drug Itolizumab for treating patients having moderate-to-severe Covid-19 complications. Biocon shares soared to an intra-day high of Rs 455, up 9.8 per cent, at opening bell. At 9:52 am, the shares had surrendered a substantial part of their early gains and were trading at Rs 422, higher by Rs 422, or 1.9 per cent, on the BSE.
Biocon received the DCGI's approval to market Itolizumab injection solution in India for treating cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19, the company had said in a regulatory filing on Saturday.
Itolizumab is the first novel biologic therapy to be approved in the world for treating patients with moderate to severe COVID-19 complications.
Itolizumab will be manufactured in the form of an intravenous injection at Biocon's bio-manufacturing facility located at Biocon Park in Bengaluru.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, "As an innovation-led biopharmaceuticals company, I am proud of the successful outcome of the pivotal study we conducted with our novel immuno-modulating anti-CD6 monoclonal antibody, Itolizumab, which has proven to be an efficacious intervention in treating the serious hyper immune response seen with COVID-19. The data is compelling and I am confident that this 'first-in-class' biologic will save lives and help reduce the mortality rate in our country."
The BSE Sensex was trading at 36,931, higher by 343 points or 0.9 per cent and the NSE Nifty was at 10,868, up 100 points or 0.9 per cent at the time.Â
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
